Novo Sees Brighter China Outlook As Volumes Rise
Executive Summary
Novo Nordisk says its China business is regaining strength, helped by improved volumes and broad growth in the diabetes sector and despite pricing pressures, and sees a brighter outlook ahead of the local approval of Tresiba.